Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors.

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

New Screening Tool Could Improve the Survival Rate of Patients With Hepatocellular Carcinoma from 20% to ... cirrhosis and other serious health ... Mechanism of Action of the Hepatitis B and ...

A recent study reveals how a diet high in fats and sugars can damage DNA, thereby increasing the risk of liver cancer in ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply ...

"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated risk of mortality in its ...

The FDA has granted Orphan Drug Designation to amezalpat for the treatment of hepatocellular carcinoma ... is consistent with amezalpat’s proposed mechanism of action to target both the tumor ...

From Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Victoria, Australia (R.H.R.) Division of Endocrinology and Metabolism (E.D.A.), ...

CY-101 is under clinical development by Cytovation and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs for Lymphoma have a 30% phase transition success rate (PTSR) ...